Fiera Capital Corp Trims Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Fiera Capital Corp lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,219,189 shares of the company’s stock after selling 38,775 shares during the period. Fiera Capital Corp’s holdings in SpringWorks Therapeutics were worth $44,049,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in SWTX. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of SpringWorks Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock valued at $87,000 after purchasing an additional 474 shares during the last quarter. KBC Group NV lifted its stake in SpringWorks Therapeutics by 59.1% in the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after buying an additional 978 shares during the last quarter. Quantbot Technologies LP purchased a new stake in SpringWorks Therapeutics in the third quarter valued at approximately $147,000. Quarry LP boosted its holdings in shares of SpringWorks Therapeutics by 20.0% in the third quarter. Quarry LP now owns 6,000 shares of the company’s stock valued at $192,000 after acquiring an additional 1,000 shares during the period. Finally, Park Avenue Securities LLC purchased a new position in shares of SpringWorks Therapeutics during the fourth quarter worth approximately $203,000.

SpringWorks Therapeutics Price Performance

Shares of SWTX stock opened at $59.28 on Thursday. SpringWorks Therapeutics, Inc. has a 12-month low of $28.21 and a 12-month high of $60.00. The stock has a 50 day simple moving average of $38.35 and a 200-day simple moving average of $36.40.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The company had revenue of $49.10 million during the quarter, compared to the consensus estimate of $53.28 million. During the same quarter last year, the company earned ($1.27) earnings per share. SpringWorks Therapeutics’s quarterly revenue was up 4810.0% compared to the same quarter last year. Sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the completion of the transaction, the insider now directly owns 50,762 shares in the company, valued at approximately $2,759,422.32. This trade represents a 36.95 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares of the company’s stock, valued at approximately $8,796,912. The trade was a 8.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 302,750 shares of company stock worth $16,139,410 over the last 90 days. Company insiders own 7.61% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on SWTX shares. Wedbush reiterated an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research report on Monday. Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Wednesday. Finally, Guggenheim lowered their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average target price of $70.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.